A biotechnology company, which designs, optimizes and develops novel drugs that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases, and viral infections.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
BioCryst stock has roared northward from the December low of 2.29 along with many other dubious biotechs in the counterintuitive rising tide of 2012. In some cases it was a recovery long overdue. In the case of BioCryst, not so much. The activating catalyst seems to be gout drug BCX4208, whose phase IIb data was released to a loud collective yawn last October. The lack of awesomeness of the data is well-summarized here http://www.thestreet.com/_yahoo/story/11269023/1/biocrysts-gout-drug-fails-to-impress.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA . Does BCX4208 look like it's worth a 130M enterprise value?
Fodosine hasn't been mentioned since weak phase II data in 2010. That leaves peramivir, a troubled infuenza drug that the company has been struggling to advance for more than ten years. In fairness, the intravenous form of peramivir is now in a phase III trial with results expected in mid-2012, but given prior failures I have low expectations. BioCryst may be rising on broad market strength and biotech acquisition froth but I think they're going to be one of the first stocks thrown under the bus when the worm turns.